Cargando…
Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9
BACKGROUND: Interleukin (IL)-9 is a Th2-derived cytokine with pleiotropic biological effects, which recently has been proposed as a candidate gene for asthma and allergy. We aimed to evaluate the therapeutic effect of a neutralizing anti-IL-9 antibody in a mouse model of airway eosinophilic inflamma...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090617/ https://www.ncbi.nlm.nih.gov/pubmed/15823208 http://dx.doi.org/10.1186/1465-9921-6-33 |
_version_ | 1782123904322502656 |
---|---|
author | Sitkauskiene, Brigita Rådinger, Madeleine Bossios, Apostolos Johansson, Anna-Karin Sakalauskas, Raimundas Lötvall, Jan |
author_facet | Sitkauskiene, Brigita Rådinger, Madeleine Bossios, Apostolos Johansson, Anna-Karin Sakalauskas, Raimundas Lötvall, Jan |
author_sort | Sitkauskiene, Brigita |
collection | PubMed |
description | BACKGROUND: Interleukin (IL)-9 is a Th2-derived cytokine with pleiotropic biological effects, which recently has been proposed as a candidate gene for asthma and allergy. We aimed to evaluate the therapeutic effect of a neutralizing anti-IL-9 antibody in a mouse model of airway eosinophilic inflammation and compared any such effect with anti-IL-5 treatment. METHODS: OVA-sensitized Balb/c mice were intraperitoneally pretreated with a single dose (100 μg) of an anti-mouse IL-9 monoclonal antibody (clone D9302C12) or its vehicle. A third group was given 50 μg of a monoclonal anti-mouse IL-5 antibody (TRFK-5) or its vehicle. Animals were subsequently exposed to OVA on five days via airways. Newly produced eosinophils were labelled using 5-bromo-2'-deoxyuridine (BrdU). BrdU(+ )eosinophils and CD34(+ )cell numbers were examined by immunocytochemistry. After culture and stimulation with OVA or PMA+IC, intracellular staining of IL-9 in bone marrow cells from OVA-exposed animals was measured by Flow Cytometry. The Mann-Whitney U-test was used to determine significant differences between groups. RESULTS: Anti-IL-9 significantly reduced bone marrow eosinophilia, primarily by decrease of newly produced (BrdU(+)) and mature eosinophils. Anti-IL-9 treatment also reduced blood neutrophil counts, but did not affect BAL neutrophils. Anti-IL-5 was able to reduce eosinophil numbers in all tissue compartments, as well as BrdU(+ )eosinophils and CD34(+ )progenitor cells, and in all instances to a greater extent than anti-IL-9. Also, FACS analysis showed that IL-9 is over-expressed in bone marrow CD4(+ )cells after allergen exposure. CONCLUSIONS: Our data shows that a single dose of a neutralizing IL-9 antibody is not sufficient to reduce allergen-induced influx of newly produced cells from bone marrow to airways. However, in response to allergen, bone marrow cells over-express IL-9. This data suggest that IL-9 may participate in the regulation of granulocytopoiesis in allergic inflammation. |
format | Text |
id | pubmed-1090617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-10906172005-05-07 Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9 Sitkauskiene, Brigita Rådinger, Madeleine Bossios, Apostolos Johansson, Anna-Karin Sakalauskas, Raimundas Lötvall, Jan Respir Res Research BACKGROUND: Interleukin (IL)-9 is a Th2-derived cytokine with pleiotropic biological effects, which recently has been proposed as a candidate gene for asthma and allergy. We aimed to evaluate the therapeutic effect of a neutralizing anti-IL-9 antibody in a mouse model of airway eosinophilic inflammation and compared any such effect with anti-IL-5 treatment. METHODS: OVA-sensitized Balb/c mice were intraperitoneally pretreated with a single dose (100 μg) of an anti-mouse IL-9 monoclonal antibody (clone D9302C12) or its vehicle. A third group was given 50 μg of a monoclonal anti-mouse IL-5 antibody (TRFK-5) or its vehicle. Animals were subsequently exposed to OVA on five days via airways. Newly produced eosinophils were labelled using 5-bromo-2'-deoxyuridine (BrdU). BrdU(+ )eosinophils and CD34(+ )cell numbers were examined by immunocytochemistry. After culture and stimulation with OVA or PMA+IC, intracellular staining of IL-9 in bone marrow cells from OVA-exposed animals was measured by Flow Cytometry. The Mann-Whitney U-test was used to determine significant differences between groups. RESULTS: Anti-IL-9 significantly reduced bone marrow eosinophilia, primarily by decrease of newly produced (BrdU(+)) and mature eosinophils. Anti-IL-9 treatment also reduced blood neutrophil counts, but did not affect BAL neutrophils. Anti-IL-5 was able to reduce eosinophil numbers in all tissue compartments, as well as BrdU(+ )eosinophils and CD34(+ )progenitor cells, and in all instances to a greater extent than anti-IL-9. Also, FACS analysis showed that IL-9 is over-expressed in bone marrow CD4(+ )cells after allergen exposure. CONCLUSIONS: Our data shows that a single dose of a neutralizing IL-9 antibody is not sufficient to reduce allergen-induced influx of newly produced cells from bone marrow to airways. However, in response to allergen, bone marrow cells over-express IL-9. This data suggest that IL-9 may participate in the regulation of granulocytopoiesis in allergic inflammation. BioMed Central 2005 2005-04-11 /pmc/articles/PMC1090617/ /pubmed/15823208 http://dx.doi.org/10.1186/1465-9921-6-33 Text en Copyright © 2005 Sitkauskiene et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Sitkauskiene, Brigita Rådinger, Madeleine Bossios, Apostolos Johansson, Anna-Karin Sakalauskas, Raimundas Lötvall, Jan Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9 |
title | Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9 |
title_full | Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9 |
title_fullStr | Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9 |
title_full_unstemmed | Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9 |
title_short | Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9 |
title_sort | airway allergen exposure stimulates bone marrow eosinophilia partly via il-9 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090617/ https://www.ncbi.nlm.nih.gov/pubmed/15823208 http://dx.doi.org/10.1186/1465-9921-6-33 |
work_keys_str_mv | AT sitkauskienebrigita airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9 AT radingermadeleine airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9 AT bossiosapostolos airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9 AT johanssonannakarin airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9 AT sakalauskasraimundas airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9 AT lotvalljan airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9 |